Suramin Sodium has been observed as a potent inhibitor of melanoma HPA (heparanase) and tumor cell metastasis. Inhibition of NAD+-dependent deacetylase SIRT1 with an IC50 of 2.6 ?M along with SIRT5 has also been observed. Suramin Sodium has been recorded to antagonize EDG-3 (S1P3) selectively. Suramin Sodium is an inhibitor of A cyclase, FGF-1, FGF-2, IL-1, IL-4, PDGF, PC-PLD, PKC, SH-PTP, TERT, TGF beta 1, Topo I, Topo II and VEGF. It is used as a G protein uncoupler and inhibitor of PDGF, EGF, TGF-β, SIRT1 and SIRT5. It also blocks calmodulin binding to recognition sites and G protein coupling to G protein-coupled receptors. Increases open probability of ryanodine receptor (RyR) channels. Anticancer and antiviral agent.
Voogd et al. Recent research on the biological activity of suramin. Pharmacol.Rev. < span>1993, 45, (2), 177-203.
Beindl et al. Inhibition of receptor/G protein coupling by suramin analogues. Mol.Pharmacol. < span>1996, 50, (2), 415-23.
Mentions de prudence: P260-P201-P280-P304+P340-P405-P501a
Do not breathe dust/fume/gas/mist/vapours/spray. Obtain special instructions before use. Wear protective gloves/protective clothing/eye protection/face protection. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.